Sign into your account to have access to your paid resources

FORGOT YOUR PASSWORD?

FORGOT YOUR DETAILS?

AAH, WAIT, I REMEMBER NOW!

Clinical Education

  • LOGIN
  • MY ACCOUNT
  • Home
  • About
    • Our Philosophy
  • Upcoming Events
    • Prescribing Lifestyle Medicine
    • Education Partnerships
  • Home Learning
    • CPD Seminars
    • nutrihub Advanced Course Part 1
  • Free Articles
    • News
    • Abstracts
    • Reviews
    • Newsletters
    • Audio
    • Video
    • Infographics
      • The Human Gut Microbiota
  • Contact
  • Home
  • News
  • Saccharomyces Boulardii Administration Changes Gut Microbiota And Reduces Hepatic Steatosis, Low-Grade Inflammation, And Fat Mass In Obese And Type 2 Diabetic Db/Db Mice.

Saccharomyces Boulardii Administration Changes Gut Microbiota And Reduces Hepatic Steatosis, Low-Grade Inflammation, And Fat Mass In Obese And Type 2 Diabetic Db/Db Mice.

by Michael Ash / Thursday, 04 June 2015 / Published in News
0
Reading Time: 2 minutes

journal_logoThe use of Saccharomyces Boulardii as a therapeutic intervention in people with alterations in their microbiota and local immune responses has been explored for over 50 years. The multiple points of action this simple yeast initiates in terms of mucosal barrier function and immune competence has made it an attractive and safe product for many clinicians. This study published in Jun 2014 in the American Society for Microbiology explores its role in a mouse model, but opens some interesting prospects for human health.[1]

Abstract

Growing evidence shows that gut microbes are key factors involved in the regulation of energy homeostasis, metabolic inflammation, lipid metabolism, and glucose metabolism. Therefore, gut microbiota modulations caused by selectively fermented oligosaccharides or probiotic bacteria constitute an interesting target in the physiopathology of obesity.

However, to date, no probiotic yeast has been investigated in this context. Therefore, our study aimed to evaluate the impact of the most-studied probiotic yeast (i.e., Saccharomyces boulardii Biocodex) on obesity and associated metabolic features, such as fat mass development, hepatic steatosis, and low-grade inflammation, in obese mice. S.boulardii was administered daily by oral gavage to leptin-resistant obese and type 2 diabetic mice (db/db) for 4 weeks. We found that S. boulardii-treated mice exhibited reduced body weight, fat mass, hepatic steatosis, and inflammatory tone.

Interestingly, these effects of S. boulardii on host metabolism were associated with local effects in the intestine. S. boulardii increased cecum weight and cecum tissue weight but also induced dramatic changes in the gut microbial composition at the phylum, family, and genus levels. These gut microbiota changes in response to S. boulardii may also be correlated with the host metabolism response.

In conclusion, this study demonstrates for the first time that S. boulardii may act as a beneficial probiotic treatment in the context of obesity and type 2 diabetes.

 Reference

[1] Everard A, Matamoros S, Geurts L, Delzenne NM, Cani PD. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. MBio. 2014 Jun 10;5(3):e01011-14. View Full Paper

Related posts:

  1. Gut Bacteria and Type 2 Diabetes
  2. Prescription Drugs Obscure Microbiome Analyses
  3. Ultra-Processed Diets Causing Weight Gain
  4. Eating All Meals within 10 Hours Aids Weight Loss
Tagged under: Diabetes, obesity, Probiotic, S. Boulardii

Leave a Reply

Click here to cancel reply.

Recent Posts

  • Nutritional Support for Parkinson’s Disease

    Reading Time: 2 minutes #Parkinson’s disease i...
  • Proven Link Between the Microbiome and the Dynamics of the Immune System

    Reading Time: 2 minutes In recent years, the #...
  • Patrick Holford Seeks Your Support For Vitamin C

    Reading Time: 3 minutes Dear practitioner Vita...
  • Using Adaptogens to Fight Respiratory Infections

    Reading Time: 2 minutes The #COVID-19 pandemic...
  • ‘Diet’ Drinks No Better for our Heart than Full Sugar Drinks

    Reading Time: < 1 minute The popularity of ...

Keywords

A(H1N1) allergies antibiotics antioxidants autism autoimmune bacteria bias brain CAM cancer cardiovascular coeliac cytokines depression detoxification diet dysbiosis EFAs evidence fatty acids gluten gut gut health IBD IBS immune immunity inflammation microbiome microbiota mucosal nutrition obesity pregnancy prevention probiotics regulatory T cells research swine flu treatment virus Vitamin A vitamin D vitamins

Updates on your email

Don't miss out on our email updates

FACEBOOK

TWITTER

Tweets by @officalclined

CONTACT

Phone: 0333 241 4289
Fax: 08450 760 403

Clinical Education
Nutrition House
24 Milber Trading Estate
Newton Abbot
Devon
TQ12 4SG
United Kingdom

 
Clinical Education

© 2021 Copyright Clinical Education. All rights reserved.

TOP
We use cookies and similar tools across our websites to improve their performance and enhance your user experience. I understand Learn more
Privacy & Cookies Policy
Necessary Always Enabled